Haj Amer, Doenitz Christian, Schebesch Karl-Michael, Ehrensberger Denise, Hau Peter, Putnik Kurt, Riemenschneider Markus J, Wendl Christina, Gerken Michael, Pukrop Tobias, Brawanski Alexander, Proescholdt Martin A
Wilhelm Sander Neuro-Oncology Unit, University Medical Center Regensburg, 93053 Regensburg, Germany.
Department of Neurosurgery, University Medical Center Regensburg, 93053 Regensburg, Germany.
Brain Sci. 2017 Dec 25;8(1):5. doi: 10.3390/brainsci8010005.
Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided resection, and integrated postsurgical therapy. This study analyzed whether the technically improved neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving patient outcome.
The study included 149 patients treated surgically for newly diagnosed GBM. The neurological performance score (NPS) and the Karnofsky performance score (KPS) were measured before and after resection. The extent of resection (EOR) was volumetrically quantified. Patients were stratified into two subcohorts: treated before (A) and after (B) the foundation of the Regensburg NOC. The EOR and the PFS and OS were evaluated.
Prognostic factors for PFS and OS were age, preoperative KPS, O⁶-methylguanine-DNA-methyltransferase () promoter methylation status, isocitrate dehydrogenase 1 () mutation status and EOR. Patients with volumetrically defined complete resection had significantly better PFS (9.4 vs. 7.8 months; = 0.042) and OS (18.4 vs. 14.5 months; = 0.005) than patients with incomplete resection. The frequency of transient or permanent postoperative neurological deficits was not higher after complete resection in both subcohorts. The frequency of complete resection was significantly higher in subcohort B than in subcohort A (68.2% vs. 34.8%; = 0.007). Accordingly, subcohort B showed significantly longer PFS (8.6 vs. 7.5 months; = 0.010) and OS (18.7 vs. 12.4 months; = 0.001). Multivariate Cox regression analysis showed complete resection, age, preoperative KPS, and promoter status as independent prognostic factors for PFS and OS. Our data show a higher frequency of complete resection in patients with GBM after the establishment of a series of technical developments that resulted in significantly better PFS and OS without increasing surgery-related morbidity.
胶质母细胞瘤(GBM)的治疗包括显微手术切除,随后进行同步放化疗和辅助化疗。无进展生存期(PFS)和总生存期(OS)的最佳结果是通过最大程度切除实现的。专业神经肿瘤护理中心(NOC)的建立使得能够实施一系列技术手段,包括功能成像、清醒开颅手术、PET扫描、荧光引导切除以及综合术后治疗。本研究分析了技术改进后的神经外科治疗结构是否能提高完全切除率,从而最终改善患者预后。
本研究纳入了149例接受手术治疗的新诊断GBM患者。在切除前后测量神经功能评分(NPS)和卡诺夫斯基功能状态评分(KPS)。通过体积法对切除范围(EOR)进行量化。患者被分为两个亚组:在雷根斯堡NOC建立之前(A组)和之后(B组)接受治疗。评估EOR、PFS和OS。
PFS和OS的预后因素包括年龄、术前KPS、O⁶ - 甲基鸟嘌呤 - DNA甲基转移酶()启动子甲基化状态、异柠檬酸脱氢酶1()突变状态和EOR。体积法定义的完全切除患者的PFS(9.4个月对7.8个月; = 0.042)和OS(18.4个月对14.5个月; = 0.005)显著优于不完全切除患者。在两个亚组中,完全切除后短暂或永久性术后神经功能缺损的发生率均未更高。B组的完全切除频率显著高于A组(68.2%对34.8%; = 0.007)。相应地,B组的PFS(8.6个月对7.5个月; = 0.010)和OS(18.7个月对12.4个月; = 0.001)显著更长。多因素Cox回归分析显示完全切除、年龄、术前KPS和启动子状态是PFS和OS的独立预后因素。我们的数据显示,在一系列技术发展建立后,GBM患者的完全切除频率更高,这导致PFS和OS显著改善,且未增加手术相关发病率。